Published in Blood on October 24, 2002
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell (2009) 2.42
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov (2015) 2.29
Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood (2008) 2.15
Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol (2006) 2.01
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. Ann N Y Acad Sci (2005) 1.44
B cell-specific loss of histone 3 lysine 9 methylation in the V(H) locus depends on Pax5. Nat Immunol (2004) 1.34
Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Res (2005) 1.29
Myc roles in hematopoiesis and leukemia. Genes Cancer (2010) 1.23
c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol Ther (2008) 1.15
CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest (2012) 1.09
Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia. Blood (2015) 1.08
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun (2016) 1.05
B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. J Clin Invest (2007) 1.05
2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated impairment of B cell differentiation involves dysregulation of paired box 5 (Pax5) isoform, Pax5a. J Pharmacol Exp Ther (2008) 0.98
The histopathologic and molecular basis for the diagnosis of histiocytic sarcoma and histiocyte-associated lymphoma of mice. Vet Pathol (2010) 0.97
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood (2007) 0.93
Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors. J Cell Sci (2013) 0.87
Clonal conversion of B lymphoid leukemia reveals cross-lineage transfer of malignant states. Genes Dev (2016) 0.84
B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages. Exp Cell Res (2006) 0.83
Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects. PLoS One (2013) 0.82
Epigenetic histone modifications do not control Igkappa locus contraction and intranuclear localization in cells with dual B cell-macrophage potential. J Immunol (2006) 0.81
Increased expression of PcG protein YY1 negatively regulates B cell development while allowing accumulation of myeloid cells and LT-HSC cells. PLoS One (2012) 0.81
Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. Oncogene (2013) 0.81
Independent development of lymphoid and histiocytic malignancies from a shared early precursor. Leukemia (2015) 0.75
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature (1999) 5.77
Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity (1999) 5.34
Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell (2002) 5.29
Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature (1995) 4.14
The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J Exp Med (1993) 3.57
Identification of the earliest B lineage stage in mouse bone marrow. Immunity (1996) 2.62
Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors. Nature (1999) 2.36
Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A. Immunity (1999) 2.35
Reprogramming of genome function through epigenetic inheritance. Nature (2001) 2.24
Do stem cells play dice? Blood (1998) 2.19
Reversion of B cell commitment upon loss of Pax5 expression. Science (2002) 2.16
Induction of early B cell factor (EBF) and multiple B lineage genes by the basic helix-loop-helix transcription factor E12. J Exp Med (1998) 2.08
Bipotential precursors of B cells and macrophages in murine fetal liver. Nature (1992) 2.03
Dissecting the role of N-myc in development using a single targeting vector to generate a series of alleles. Curr Biol (1998) 2.02
EBF and E47 collaborate to induce expression of the endogenous immunoglobulin surrogate light chain genes. Immunity (1997) 1.95
The B/macrophage cell: an elusive link between CD5+ B lymphocytes and macrophages. Immunol Today (1996) 1.94
Lineage promiscuity in hemopoietic differentiation and leukemia. Blood (1986) 1.91
A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene (2002) 1.70
Bipotential B-macrophage progenitors are present in adult bone marrow. Nat Immunol (2001) 1.65
Lineage commitment and maturation in hematopoietic cells: the case for extrinsic regulation. Blood (1998) 1.49
Hemopoietic lineage switch: v-raf oncogene converts Emu-myc transgenic B cells into macrophages. Cell (1988) 1.40
The influence of S17 stromal cells and interleukin 7 on B cell development. Eur J Immunol (1990) 1.35
BSAP can repress enhancer activity by targeting PU.1 function. Mol Cell Biol (2000) 1.12
Lineage commitment in lymphopoiesis. Curr Opin Immunol (2000) 1.06
Relationships between B cell and myeloid differentiation. Studies with a B lymphocyte progenitor line, HAFTL-1. J Exp Med (1988) 1.05
Transcription factor regulation of B lineage commitment. Curr Opin Immunol (2001) 0.99
BSAP/Pax5A expression blocks survival and expansion of early myeloid cells implicating its involvement in maintaining commitment to the B-lymphocyte lineage. Blood (1999) 0.88
Role for transcription Pax5A factor in maintaining commitment to the B cell lineage by selective inhibition of granulocyte-macrophage colony-stimulating factor receptor expression. J Immunol (2001) 0.82
Characterization of a 70Z/3 pre-B cell derived macrophage clone. Differential expression of Hox family genes. Int Immunol (1990) 0.82
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest (2007) 9.33
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 3.43
Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood (2004) 2.90
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell (2010) 2.38
Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5. Nat Immunol (2008) 2.19
The decline in B lymphopoiesis in aged mice reflects loss of very early B-lineage precursors. J Immunol (2003) 2.17
The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res (2010) 2.13
Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol (2006) 2.01
Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol (2008) 1.96
Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood (2005) 1.96
Transcription factor YY1 functions as a PcG protein in vivo. EMBO J (2003) 1.95
Characterization of marginal zone B cell precursors. J Exp Med (2005) 1.92
Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci U S A (2005) 1.91
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest (2012) 1.85
Polycomb recruitment to DNA in vivo by the YY1 REPO domain. Proc Natl Acad Sci U S A (2006) 1.82
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol (2002) 1.70
A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene (2002) 1.70
Sumoylation of Oct4 enhances its stability, DNA binding, and transactivation. J Biol Chem (2007) 1.65
Generation of peripheral B cells occurs via two spatially and temporally distinct pathways. Blood (2006) 1.61
The earliest step in B lineage differentiation from common lymphoid progenitors is critically dependent upon interleukin 7. J Exp Med (2002) 1.61
B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev (2010) 1.60
Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1. Immunity (2002) 1.55
B lineage-specific regulation of V(D)J recombinase activity is established in common lymphoid progenitors. J Exp Med (2004) 1.53
An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth. Cancer Biol Ther (2003) 1.52
YY1 DNA binding and PcG recruitment requires CtBP. Genes Dev (2004) 1.52
Transitional B cells: step by step towards immune competence. Trends Immunol (2003) 1.50
Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. Ann N Y Acad Sci (2005) 1.44
B cell-specific loss of histone 3 lysine 9 methylation in the V(H) locus depends on Pax5. Nat Immunol (2004) 1.34
MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells in three-dimensional culture. J Exp Med (2005) 1.34
Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Res (2007) 1.30
Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Res (2005) 1.29
Visualizing PU.1 activity during hematopoiesis. Exp Hematol (2005) 1.28
Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog (2013) 1.28
Detection of Bartonella henselae and Bartonella clarridgeiae DNA in hepatic specimens from two dogs with hepatic disease. J Am Vet Med Assoc (2003) 1.24
Differential requirement for LAT and SLP-76 in GPVI versus T cell receptor signaling. J Exp Med (2002) 1.24
Rapid B cell receptor-induced unfolded protein response in nonsecretory B cells correlates with pro- versus antiapoptotic cell fate. J Biol Chem (2005) 1.23
Basal B-cell receptor signaling in B lymphocytes: mechanisms of regulation and role in positive selection, differentiation, and peripheral survival. Immunol Rev (2004) 1.22
Regulation of peripheral B cell maturation. Cell Immunol (2006) 1.21
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res (2013) 1.20
Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst (2009) 1.19
Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res (2005) 1.16
c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol Ther (2008) 1.15
Early growth response genes regulate B cell development, proliferation, and immune response. J Immunol (2008) 1.14
p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res (2011) 1.14
Notch activity synergizes with B-cell-receptor and CD40 signaling to enhance B-cell activation. Blood (2006) 1.13
Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood (2009) 1.13
Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther (2011) 1.12
CD23 defines two distinct subsets of immature B cells which differ in their responses to T cell help signals. Int Immunol (2002) 1.10
Models for peripheral B cell development and homeostasis. Semin Immunol (2005) 1.10
An immunoreceptor tyrosine activation motif in the mouse mammary tumor virus envelope protein plays a role in virus-induced mammary tumors. J Virol (2006) 1.10
c-Myb is required for pro-B cell differentiation. J Immunol (2009) 1.10
CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest (2012) 1.09
Early T lineage progenitors: new insights, but old questions remain. J Immunol (2003) 1.08
Development and selection of edited B cells in B6.56R mice. J Immunol (2006) 1.08
Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model. Cancer Res (2009) 1.08
Mouse plasmacytoid dendritic cells derive exclusively from estrogen-resistant myeloid progenitors. Blood (2006) 1.05
B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. J Clin Invest (2007) 1.05
Transient requirements of YY1 expression for PcG transcriptional repression and phenotypic rescue. J Cell Biochem (2005) 1.04
Linking age-related defects in B lymphopoiesis to the aging of hematopoietic stem cells. Semin Immunol (2005) 1.03
Extensive replicative capacity of human central memory T cells. J Immunol (2004) 1.02
Resolution of unique Sca-1highc-Kit- lymphoid-biased progenitors in adult bone marrow. J Immunol (2008) 1.01
Transcriptional regulation of the cyclooxygenase-2 gene in macrophages by PU.1. J Biol Chem (2003) 1.01
Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI. J Clin Invest (2011) 1.01
Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum (2011) 1.01
Control of New World cutaneous leishmaniasis is IL-12 independent but STAT4 dependent. Eur J Immunol (2002) 1.00
Proliferative and necrotizing otitis externa in four cats. Vet Dermatol (2007) 0.99
NF-kappaB inducible genes BCL-X and cyclin E promote immature B-cell proliferation and survival. Cell Immunol (2005) 0.99
Membrane cholesterol content accounts for developmental differences in surface B cell receptor compartmentalization and signaling. J Biol Chem (2005) 0.97
Long-lived bone marrow plasma cells are induced early in response to T cell-independent or T cell-dependent antigens. J Immunol (2012) 0.97
NF-kappa B2 is required for optimal CD40-induced IL-12 production but dispensable for Th1 cell Differentiation. J Immunol (2002) 0.97
TRAF6 is required for generation of the B-1a B cell compartment as well as T cell-dependent and -independent humoral immune responses. PLoS One (2009) 0.96
Protein acetylation regulates both PU.1 transactivation and Ig kappa 3' enhancer activity. J Immunol (2005) 0.96
The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood (2013) 0.96
Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. RNA (2012) 0.95
PcG recruitment by the YY1 REPO domain can be mediated by Yaf2. J Cell Biochem (2010) 0.95
B cell antigen receptor-induced Rac1 activation and Rac1-dependent spreading are impaired in transitional immature B cells due to levels of membrane cholesterol. J Immunol (2007) 0.94
Mechanism of e47-Pip interaction on DNA resulting in transcriptional synergy and activation of immunoglobulin germ line sterile transcripts. Mol Cell Biol (2002) 0.94
PU.1 can recruit BCL6 to DNA to repress gene expression in germinal center B cells. Mol Cell Biol (2009) 0.94
YY1 controls Igκ repertoire and B-cell development, and localizes with condensin on the Igκ locus. EMBO J (2013) 0.94
The role of MAPKs in B cell receptor-induced down-regulation of Egr-1 in immature B lymphoma cells. J Biol Chem (2006) 0.93
Incomplete activation of CD4 T cells by antigen-presenting transitional immature B cells: implications for peripheral B and T cell responsiveness. J Immunol (2003) 0.93
Transcriptional regulation of early B cell development. Immunol Res (2008) 0.93
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood (2007) 0.93
Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol Ther (2007) 0.93
Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis. Adv Cancer Res (2009) 0.93
A comparison of the effects of propofol and etomidate on the induction of anesthesia and on cardiopulmonary parameters in dogs. Vet Anaesth Analg (2008) 0.91
YY1 DNA binding and interaction with YAF2 is essential for Polycomb recruitment. Nucleic Acids Res (2013) 0.90
Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes. J Immunol (2004) 0.89
Transcriptional repression of Gata3 is essential for early B cell commitment. Immunity (2013) 0.89
Tonic B-cell and viral ITAM signaling: context is everything. Immunol Rev (2007) 0.88
Clinical and immunohistochemical differentiation of gastrointestinal stromal tumors from leiomyosarcomas in dogs: 42 cases (1990-2003). J Am Vet Med Assoc (2007) 0.87
The Ig kappa 3' enhancer is activated by gradients of chromatin accessibility and protein association. J Immunol (2005) 0.86